{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:06:44Z","timestamp":1790089604082,"version":"4.0.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Maintenance treatment in older patients with relapsed or refractory (R\/R) follicular lymphoma (FL) remains an area of investigation. RENOIR was a multicenter, phase 3, open-label randomized trial conducted by the Fondazione Italiana Linfomi (FIL) in older patients with R\/R FL after 1 or 2 previous therapies. Patients achieving partial response or complete response (CR) after 4 to 6 cycles of standard rituximab (R)\u2013based chemotherapy were randomized 1:1 to maintenance with R alone (standard arm) or R plus lenalidomide (R2; experimental arm). The primary end point was 2-year progression-free survival (PFS) from randomization, with an expected hazard ratio (HR) of 0.5. A total of 152 patients (median age, 71 years) were enrolled. After induction, 129 (85%) achieved an overall response (CR, 58%) and were randomized to R (n = 65) or R2 (n = 64). At a median follow-up of 68 months, the 2-year PFS was 73% in the R2 arm and 64% in the R arm. An unplanned hypothesis-generating subgroup analysis showed a greater 2-year PFS benefit with R2 in patients aged &amp;lt;70 years: R2, 96% vs R, 69%. Two-year overall survival rates were similar (R2, 80% vs R, 89%). Grade 3\/4 adverse events were more frequent in R2, mainly neutropenia and gastrointestinal disorders. In conclusion, the primary end point of the study was not met, and R2 maintenance did not significantly improve 2-year PFS in older patients with R\/R FL, although a numerical benefit was observed. R2 showed a more favorable benefit-risk profile in patients aged &amp;lt;70 years, whereas in older patients careful consideration of individual tolerability is warranted. This trial was registered at www.clinicaltrials.gov as NCT02390869.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018732","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:54:18Z","timestamp":1782424458000},"page":"6208-6220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed\/refractory follicular lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7514-6172","authenticated-orcid":false,"given":"Barbara","family":"Botto","sequence":"first","affiliation":[{"name":"1Ematologia, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[{"name":"1Ematologia, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[{"name":"2Epidemiologia Clinica e Valutativa, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza and CPO Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[{"name":"3Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Anastasia","sequence":"additional","affiliation":[{"name":"4Ematologia, ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-1099","authenticated-orcid":false,"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"5Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy"},{"name":"6Division of Hematology and Stem Cell Transplant Unit, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"7Ematologia, AUSL-IRCCS, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Zanni","sequence":"additional","affiliation":[{"name":"8Ematologia, Dipartimento di Medicina Traslazionale, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"9Ematologia, Ospedale delle Croci, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[{"name":"1Ematologia, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"},{"name":"10Ematologia, Azienda Ospedaliero-Universitaria Policlinico \"G. Rodolico\u2013S. Marco,\" Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"11Oncoematologia, Azienda Ospedaliera Santa Maria, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Conconi","sequence":"additional","affiliation":[{"name":"12Ematologia, Nuovo Ospedale degli Infermi, Biella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rusconi","sequence":"additional","affiliation":[{"name":"13Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-2499","authenticated-orcid":false,"given":"Alessia","family":"Bari","sequence":"additional","affiliation":[{"name":"14Oncologia, Policlinico di Modena, Universit\u00e0 di Modena e Reggio Emilia, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"15Ematologia, Policlinico Umberto I, \"Sapienza\" University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-0151","authenticated-orcid":false,"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"16Ematologia, Dipartimento di Medicina Traslazionale, Universit\u00e0 del Piemonte Orientale, AOU Maggiore della Carit\u00e0, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"17IRCCS Centro di Riferimento Oncologico di Aviano, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3420-3204","authenticated-orcid":false,"given":"Nilla","family":"Maschio","sequence":"additional","affiliation":[{"name":"26Oncologia 1, IRCCS Istituto Oncologico Veneto, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Castellino","sequence":"additional","affiliation":[{"name":"18Ematologia, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-6390","authenticated-orcid":false,"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[{"name":"19Onco-Ematologia, Candiolo Cancer Institute, Fondazione del Piemonte per l\u2019Oncologia, IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"20Unit\u00e0 Ematologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[{"name":"21Ematologia, Ospedale Guglielmo da Saliceto, Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bigliardi","sequence":"additional","affiliation":[{"name":"22Oncologia, Nuovo Ospedale Civile di Sassuolo, Sassuolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Matta","sequence":"additional","affiliation":[{"name":"23Ematologia, Ospedale di Ciri\u00e8, Chivasso e Ivrea, Ospedali Riuniti del Canavese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Bianchi","sequence":"additional","affiliation":[{"name":"24Ematologia, Ospedale di Circolo, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"25Ematologia, Azienda Ospedaliera Papardo, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Marino","sequence":"additional","affiliation":[{"name":"26Oncologia 1, IRCCS Istituto Oncologico Veneto, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[{"name":"27Ematologia, Ospedale C. e G. Mazzoni, Ascoli Piceno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Ciambelli","sequence":"additional","affiliation":[{"name":"28Ematologia, ASST Valle Olona\u2013Ospedale di Circolo di Busto Arsizio, Busto Arsizio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1032","authenticated-orcid":false,"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"29Ematologia, IRCCS Istituto Romagnolo per lo Studio dei Tumori \"Dino Amadori,\" Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-3222","authenticated-orcid":false,"given":"Cristina","family":"Muzi","sequence":"additional","affiliation":[{"name":"3Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1062-950X","authenticated-orcid":false,"given":"Chiara","family":"Bottelli","sequence":"additional","affiliation":[{"name":"4Ematologia, ASST Spedali Civili, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-0337","authenticated-orcid":false,"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[{"name":"5Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy"},{"name":"6Division of Hematology and Stem Cell Transplant Unit, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Meli","sequence":"additional","affiliation":[{"name":"3Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"5Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy"},{"name":"6Division of Hematology and Stem Cell Transplant Unit, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"30Surgical, Medical, and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"8Ematologia, Dipartimento di Medicina Traslazionale, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-9574","authenticated-orcid":false,"given":"Giovannino","family":"Ciccone","sequence":"additional","affiliation":[{"name":"2Epidemiologia Clinica e Valutativa, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza and CPO Piemonte, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"19Onco-Ematologia, Candiolo Cancer Institute, Fondazione del Piemonte per l\u2019Oncologia, IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"2","key":"2026092210531283900_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/modpathol.3880035","article-title":"The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997","volume":"13","author":"Harris","year":"2000","journal-title":"Mod Pathol"},{"issue":"9759","key":"2026092210531283900_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"2026092210531283900_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026092210531283900_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"issue":"28","key":"2026092210531283900_bib5","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026092210531283900_bib6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026092210531283900_bib7","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026092210531283900_bib8","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"32","key":"2026092210531283900_bib9","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026092210531283900_bib10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026092210531283900_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"issue":"14","key":"2026092210531283900_bib12","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2026092210531283900_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/01.HS9.0000847492.88194.df","article-title":"P1156: magnify phase 3B study of lenalidomide + rituximab (R2) followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma: complete induction phase analysis","volume":"6","author":"Lansigan","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2026092210531283900_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"issue":"27","key":"2026092210531283900_bib15","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2012.44.8290","article-title":"Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi","volume":"31","author":"Vitolo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026092210531283900_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.17283","article-title":"A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL)","volume":"193","author":"Boccomini","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2026092210531283900_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"2026092210531283900_bib18","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Van Oers","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026092210531283900_bib19","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"31","key":"2026092210531283900_bib20","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance)","volume":"33","author":"Leonard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026092210531283900_bib21","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026092210531283900_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2023-173692","article-title":"Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026092210531283900_bib23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026092210531283900_bib24","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2022-157729","article-title":"Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study","volume":"140","author":"Budde","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092210531283900_bib25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"10306","key":"2026092210531283900_bib26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"2026092210531283900_bib27","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026092210531283900_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026092210531283900_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-133820","article-title":"Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed\/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data","volume":"136","author":"Hutchings","year":"2020","journal-title":"Blood"},{"key":"2026092210531283900_bib30","unstructured":"FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma. FDA. 2024. Accessed 14 March 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma."},{"issue":"8","key":"2026092210531283900_bib31","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026092210531283900_bib32","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026092210531283900_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092210531283900_bib34","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2023-181650","article-title":"Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) with extended follow-up","volume":"142","author":"Villasboas","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092210531283900_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092210531283900_bib36","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood-2023-180473","article-title":"Marsun, a phase III, multicenter, open label, randomized, controlled study investigating mosunetuzumab-lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma (R\/R MZL)","volume":"142","author":"Thieblemont","year":"2023","journal-title":"Blood"},{"issue":"suppl","key":"2026092210531283900_bib37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/01.HS9.0000847408.61609.bd","article-title":"P1135: subcutaneous epcoritamab in combination with ritxuimab + lenalidomide in relapsed or refractory follicular lymphoma: phase 1\/2 trial update","volume":"6","author":"Belada","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2026092210531283900_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the Epcore NHL-2 trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"issue":"10524","key":"2026092210531283900_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"issue":"suppl 2","key":"2026092210531283900_bib40","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND)","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"10524","key":"2026092210531283900_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","volume":"407","author":"Sehn","year":"2026","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6208\/2588327\/blooda_adv-2025-018732-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6208\/2588327\/blooda_adv-2025-018732-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:53:23Z","timestamp":1790088803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6208\/569380\/RENOIR-phase-3-rituximab-lenalidomide-vs-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":41,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018732","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,11]]}}}